MSTN and cancer: An upregulation of myostatin has been shown in several disease models including cancer cachexia, chemotherapy, kidney failure, heart failure, spinal muscular atrophy, vitamin D deficiency in infantile nephropathic cystinosis, and oculopharyngeal muscular dystrophy (20–22).